SCHEMBL16197852

SCHEMBL16197852

CCC(CNC(=O)O)c1cc(=O)oc2cc(O)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B3 P37058 11/20 0.51
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 4/20 0.50
AKR1B1 P15121 4/20 0.50
CA12 O43570 4/20 0.50
CA9 Q16790 4/20 0.50
GAA P10253 3/20 0.50
GLA P06280 3/20 0.50
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
HPGD P15428 2/20 0.50
MAOB P27338 2/20 0.50
CYP2C9 P11712 1/20 0.50
UGT1A1 P22309 1/20 0.50
CASP1 P29466 1/20 0.50
KDR P35968 1/20 0.50
CASP7 P55210 1/20 0.50
MCL1 Q07820 1/20 0.50
HSD17B10 Q99714 1/20 0.50
LCK P06239 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28328438 0.86 HSD17B3 (0.63) HSD17B3ALDH1A1KDM4EAKR1B1CA12
SCHEMBL16197957 0.85 HSD17B3 (0.52) HSD17B3ALDH1A1KDM4EAKR1B1CA12
SCHEMBL30848862 0.82 ERN1 (0.46) HSD17B3ALDH1A1KDM4EAKR1B1CA12
SCHEMBL16197785 0.79 ERN1 (0.56) ALDH1A1KDM4EGAAGLALMNA
SCHEMBL17601907 0.75 HSD17B3 (0.44) HSD17B3ALDH1A1KDM4EAKR1B1CA12
SCHEMBL8961041 0.74 HSD17B3 (0.56) HSD17B3ALDH1A1KDM4EAKR1B1CA12
SCHEMBL29785167 0.73 HSD17B3 (0.63) HSD17B3ALDH1A1KDM4EAKR1B1CA12
SCHEMBL18986303 0.73 HSD17B3 (0.63) HSD17B3ALDH1A1KDM4EAKR1B1CA12
SCHEMBL17179700 0.73 ALDH1A1 (0.62) HSD17B3ALDH1A1KDM4EAKR1B1CA12
SCHEMBL27075158 0.73 AKR1B1 (0.53) HSD17B3ALDH1A1KDM4EAKR1B1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11945789-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2024-04-02 US disclosed
WO-2014176348-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945789-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof XBP1, DDIT3, ERN1 HSD17B3 2599/4885ALDH1A1 2871/4885KDM4E 2616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.